NCT06165068

Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 174 (estimated)
• Sponsor: Navamindradhiraj University · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcysteine 600 mg/day) in a dry AMD patient with large drusen. Participants will divided in to three groups. * Participants who were already taking low dose antiplatelet medications. * Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator * Participants does not use any medications.

Conditions

• Dry Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Aspirin 81Mg Ec Tab	Patients take aspirin 81 mg per day.
DRUG	Clopidogrel	Patients take clopidogrel 75 mg per day.
DRUG	N-acetylcysteine	Patients are given N-acetylcysteine 600 mg per day.

Timeline

• Start date: 2023-12-01
• Primary completion: 2025-12-01
• Completion: 2026-09-01
• First posted: 2023-12-11
• Last updated: 2023-12-15

Locations

1 site across 1 country: Thailand